CClinicalTrials.gg
CompletedNCT01986621Updated May 30, 2018

Myocardial Injury After Elective Coronary Stenting

An observational study in Coronary Artery Disease, sponsored by University Hospital Heidelberg. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-30.

Sponsored by University Hospital Heidelberg · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
530
Ages
18 Years and older
Sex
All
01

Study summary

This pilot study aims to identify patients at moderate to high risk for peri-procedural (type 4) myocardial infarction or injury after after undergoing an elective coronary intervention (PCI) as measured by high sensitivity troponin T, who might benefit from more potent antiplatelet therapy.

02

Conditions studied

  • Coronary Artery Disease

Keywords

  • Percutaneous Coronary Intervention
  • Cardiac troponin
  • Antiplatelet therapy
03

In context

Coronary Artery Disease

5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.

This study's enrollment of 530 is above the median of 336 across 1,947 observational studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

University Hospital Heidelberg is the lead sponsor of 175 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with stable or unknown CAD undergoing elective coronary intervention without receiving additional examination, such as biopsy, Ablation or any other procedure that could lead to myocardial injury resulting in elevation of the cardiac Troponin.

Inclusion criteria

  • Stable or unknown coronary artery disease (CAD)
  • Elective coronary intervention
  • Minimum age of 18

Exclusion criteria

Exclusion Criteria:

  • Present acute coronary syndrome (ACS)
  • Age under 18
  • Pregnancy
  • Any additional invasive intervention with potential myocardial injury
  • Non ACS conditions responsible for elevation of cardiac troponin, such as acute pulmonary artery embolism, myocarditis or tachycardia.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
530 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients undergoing elective PCI
06

What researchers measure

Primary outcomes

  1. Postprocedural myocardial infarction (type 4a) or injury

    Time frame: up to 72 hours after procedure

07

Study locations

1 site
  • Department of Cardiology - University Hospital of Heidelberg
    Heidelberg, 69120, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01986621
Lead sponsor
University Hospital Heidelberg
Collaborators
AstraZeneca
Responsible party
Haitham Abu Sharar (Physician, University Hospital Heidelberg) — Principal investigator
First posted
Nov 18, 2013
Start date
Apr 2014
Primary completion
Mar 2015
Completion
Jul 2015
Last update
May 30, 2018

Study contacts

Haitham Abu Sharar, Dr. med.
principal investigator · University Hospital Heidelberg
Evangelos Giannitsis, Prof. Dr.
principal investigator · University Hospital Heidelberg
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion